|16th December 2020||William Grossman||2,117||Open or private sale||$31.35||$66,367.95|
|2nd October 2020||William Grossman||100,000||Grant/award etc.||$0.00|
|31st July 2020||William Grossman||100||Open or private purchase||$19.77||$1,977.00|
|31st July 2020||William Grossman||100||Open or private purchase||$19.68||$1,967.56|
|4th June 2020||William Grossman||55,000||Grant/award etc.||$0.00|
|29th May 2020||Shane Ward||107||Payment by withholding||$7.63||$816.41|
|17th March 2020||Richard A. Fair||5,000||Open or private purchase||$4.00||$19,998.50|
|3rd January 2020||Rosemary Y. Williams||781||Exercise of derivative||$0.00|
|3rd January 2020||Alan K. Smith||1,563||Exercise of derivative||$0.00|
|3rd January 2020||Rosemary Y. Williams||295||Payment by withholding||$1.40||$413.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Bellicum Pharmaceuticals, Inc. focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. It uses its proprietary chemical induction of dimerization that controls components of the immune system in real time.